NEXT Life Sciences is developing Plan A™, a device-based, non-hormonal male contraceptive that places a biocompatible Vasalgel® hydrogel in the vas deferens to block sperm flow. Plan A™ is designed to provide up to 10 years of pregnancy prevention while remaining reversible via a dissolving procedure. NEXT acquired the worldwide license to Vasalgel® in 2022 and has since optimized the technology toward clinical development. The company plans to start clinical trials for Plan A™ in 2024 and intends to pursue FDA marketing authorization following trials. NEXT’s leadership includes experienced executives and clinicians from medical device and contraceptive fields. Financially, the company recently received a $400K grant from the Male Contraceptive Initiative and completed a prior fundraising round led by Bolt.com founder Ryan Breslow and The Family with participation from Transform VC and angel and early-stage venture investors. NEXT Life Sciences, based in Los Angeles, is a medical device company developing Plan A, a non-hormonal, long-acting, reversible on-demand male contraceptive. Plan A's design utilizes a hydrogel (Vasalgel®) that acts as a flexible filter to block sperm flow in the vas deferens. NEXT acquired the exclusive worldwide license for Vasalgel® in 2022 and aims to advance the technology through FDA authorization and to market. The company plans to start clinical trials for Plan A in 2024, followed by submission to the FDA. NEXT announced an oversubscribed $2.5M funding round led by The Family, bringing total seed funding to date to $4M. Ryan Breslow has joined as a strategic advisor, and NEXT says its executive team has prior leadership experience in medical device and contraceptive commercialization. NEXT Life Sciences is developing Plan A™, a reversible male contraceptive that uses Vasalgel®, a proprietary hydrogel the company acquired. The Plan A procedure is similar to a no‑scalpel vasectomy but inserts a hydrogel filter to block sperm flow rather than cutting the vas deferens. Preclinical studies showed rapid restoration of sperm flow after Vasalgel® was dissolved and flushed from the vas deferens. The company raised $1.55M in seed funding to support development and commercialization of Plan A. NEXT is led by CEO L.R. Fox and has assembled a Medical Advisory Board to guide contraceptive development, including Dr. Charles Carignan. The company aims to initiate clinical trials by the end of 2023.

Total raised

$4M

Funding rounds

3

Latest round

Grant

Latest activity

Feb 2024